Navigation
banner
Together we Drive the Future

Neurodegenerative Diseases Research & Development

2017-04-282017-08-112017-07-11
EARLY BIRD DISCOUNT! Register by Jul 11, 2017 to receive 20% off your registration!
Or Register 3 for the price of 2 with the coupon code rcdvb!


registration button

CNS Diseases Summit


Neurodegenerative Diseases Research & Development

CNS Partnering & Deal-Making
 
 

Subscribe for updates



Dear Colleague,

It is our pleasure to announce the 11th Neurodegenerative Diseases Research & Development Conference, to be held September 11-12, 2017 in Boston, MA. The drug discovery effort for neurodegenerative diseases has been one of the major challenges of the pharmaceutical industry. This conference will connect scientists and researchers to share perspectives on the latest topics of interest, such as targeted treatments for psychiatric disorders, neuroinflammation, and cell- and gene-therapy based therapies.

This program strives to go beyond just dialogue around research itself, but the partnerships and alliances that need to be formed in order to continue pushing research forward into the future. What are the best models of private/public partnerships? How are patient advocacy groups changing the way we think about funding and research? Colleagues will have the opportunity to build new relationships and move forward together towards the future of neuroscience.

We hope you’ll join us in Boston for a productive and informative meeting!

 
Joint Plenary Sessions:
I. Kick-off Keynote Session – Historical Perspective & State of the Industry
II. Award Ceremony & Closing Keynote Session – Predictions for future
III. Round Table Discussions: Neuroimaging & Translational Biomarkers 

11th Neurodegenerative Diseases Research & Development
I. Experimental Therapeutics & Approaches in Alzheimer’s Disease
II. Advances in Parkinson’s Disease Research & Therapeutics
III. Next Frontier in Multiple Sclerosis to Limit or Reverse Neurodegeneration
IV. Therapeutics for Rare & Orphan Neurodegenerative Diseases


Best regards,

The 2017  Advisory Committee